{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-008414","form_type":"8-K","ticker":"CMPS","cik":"0001816590","company_name":"COMPASS Pathways plc","filed_at":"2025-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.024189+00:00","generated_at":"2026-05-26T02:24:47.290429+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Compass Pathways reports FY2024 net loss of $155.1M; Phase 3 data on track for Q2 2025","bullets":["Net loss for FY2024 was $155.1M ($2.30 loss per share) vs $118.5M ($2.32 loss per share) in FY2023.","Cash and cash equivalents $165.1M at Dec 31, 2024; additional $140.4M net raised in Q1 2025.","Phase 3 COMP005 top-line 6-week data for TRD on track for Q2 2025; COMP006 26-week data expected H2 2026.","R&D expenses rose to $119.0M from $87.5M, driven by phase 3 trials and strategic reorganization costs.","Steve Levine, M.D., appointed Chief Patient Officer."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-008414","json":"https://secwatch.observer/filing/0001628280-25-008414.json","markdown":"https://secwatch.observer/filing/0001628280-25-008414.md","text":"https://secwatch.observer/filing/0001628280-25-008414.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1816590/000162828025008414/0001628280-25-008414-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1816590/000162828025008414/cmps-20250227.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T02:24:47.290429+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}